Search Results

Shanghai Henlius Biotech, Inc. (2696.HK) has entered into an exclusive license agreement with Intas Pharmaceuticals Limited (“Intas”) for the development and commercialisation in Europe and India for several indications including ES-SCLC, and specific formulation of HANSIZHUANG (serplulimab injection), Henlius’ novel anti-PD-1 mAb.

SMITM CAPITAL MARKETS LTD, has announced a significant agreement with Mid-Atlantic BioTherapeutics, Inc. (MABT), a clinical-stage ready US biopharmaceutical company.

Following reports of destroyed and discarded data, the U.S. regulator issued a warning letter to India’s Intas Pharmaceuticals regarding violations of current good manufacturing practice.

Lobe Sciences Ltd., a biopharmaceutical company focused on developing transformative medicines to treat rare diseases and Clearway Global, LLC, a wholly owned subsidiary of Sancilio & Company, a pharmaceutical services company focused on value creation strategies, are pleased to announce a change in control of the Company and several enhancements to its ongoing growth strategy.

Sanyou Biopharmaceutical Co., Ltd. is delighted to announce the official launch of the “Sanyou Intelligent Innovative Biologics R&D Service Platform,” representing a transformative advancement in biopharmaceutical research and development.